CSPACEランダム化対照試験におけるコンダクション・システム・ペーシングと右心房・セプト・ペーシングの臨床結果
Chee Loong Dominic Chow1, Chiew Wong1, Nigel Sutherland2
1Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia; Department of Cardiology, Northern Health, Melbourne, Victoria, Australia.
Journal of the American College of Cardiology
|August 20, 2025
まとめ
伝導系パッチング (CSP) は,AVブロック患者の右心室パッチングと比較して,パッチング誘発の心筋病症およびCRTアップグレードのリスクを有意に軽減します. この研究は,CSPを優れた初期ペース戦略として支持しています.
科学分野:
- 心臓病科
- 電気生理学
- 医療機器
背景:
- 右心室 (RV) のペースは,心室内膜 (AV) ブロックの患者では,ペース誘発性心筋症 (PICM),心不全の入院 (HFH),死亡などのリスクを伴う.
- 誘導システムペース (CSP) は,これらの有害な結果を軽減するための潜在的に優れたペース戦略として浮上しています.
- RVセプトペース (RVsP) のような既存のペースメソッドは,RVペースに関連した長期的な合併症を完全に対処できない可能性があります.
研究 の 目的:
- 右心室隔膜のペース (RVsP) と対照的に伝導システムペース (CSP) の臨床結果を比較する.
- ペース誘発性心筋病症 (PICM) の予防におけるCSPの有効性と,心臓再同期療法 (CRT) のアップグレードの必要性を評価する.
- 心不全の入院と全因死亡率に対するCSPの影響を評価する.
主な方法:
- ランダム化対照試験 (RCT) に参加した202人の患者で,AVブロックはペースが必要でしたが,CRTは必要ありませんでした.
- 患者は1対1でRVsPまたはCSPに分けられた.
- 主なアウトカムはPICM,CRTアップグレード,HFH,全原因死亡率の複合で,平均フォローアップ期間は25. 2ヶ月でした.
主要な成果:
- CSPは,RVsPと比較して,複合エンドポイント率 (人当たり100人当たり7. 17 vs. 20. 69; HR: 0. 35; P < 0. 001) を著しく低下させた.
- この減少は主にPICMの比率の低下 (HR: 0.31; P = 0.002) とCRTのアップグレードの必要性 (HR: 1.65e-9; P = 0.043) によって引き起こされた.
- HFHや全因死亡率は有意な差異は認められなかったが,鉛による改定はCSPではより頻繁であった (7. 9%対1. 0%; P=0. 017).
結論:
- AV阻害患者の臨床結果を改善するために,右心室隔膜阻害 (RVsP) よりも優れている.
- CSPは,PICMのような有害事象を予防し,CRT依存性を減らすための効果的な初期ペース技術として考慮されるべきです.
- CSPACE試験は,従来のRVペース戦略よりもCSPの臨床的利点を支持する強力な証拠を提供します.
関連する概念動画
Dysrhythmias IV: Characteristics of Bradyarrhythmias
118
Bradyarrhythmias are cardiac rhythm disorders characterized by a slower-than-normal heart rate, typically defined as fewer than 60 beats per minute. Some of which are discussed here:Sinus BradycardiaSinus bradycardia presents a heart rate lower than 60 beats per minute, with a regular rhythm originating from the SA node. The ECG typically shows normal P waves preceding each QRS complex, a normal PR interval (0.12 to 0.20 seconds), and a normal QRS duration (0.06 to 0.10 seconds).First-Degree AV...
118
Conduction System of the Heart
9.9K
Autorhythmicity is a term that refers to the heart's inherent ability to generate electrical signals and instigate muscle contractions. This self-regulating conduction system within the heart consists of two key components: the pacemaker cells and specialized conducting cells.
The pacemaker cells are located in two primary nodes: the sinoatrial (SA) node and the atrioventricular (AV) node. The SA node pacemaker cells can autonomously depolarize, triggering an action potential that leads to the...
The pacemaker cells are located in two primary nodes: the sinoatrial (SA) node and the atrioventricular (AV) node. The SA node pacemaker cells can autonomously depolarize, triggering an action potential that leads to the...
9.9K
Disturbances in Heart Rhythm
1.2K
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
1.2K
Dysrhythmias VI: Management of Dysrhythmias
106
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
106
Heart Failure Drugs: β-Blockers
434
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
434
Cardiomyopathy V: Interprofessional Care
33
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
33


